Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment